Table 3.

Studies on bococizumab.

S. number	Trial	Participants	Comparison	LDL reduction	Adverse events	Comments
(1)	Dose ranging trial (NCT01592240)	Those with LDL-C > 80 mg/dl on stable statin therapy	Bococizumab versus placebo	54.2% versus 2.8%	Similar adverse events profile	Despite dose reduction in many subjects, bococizumab significantly reduced LDL-C across all the doses
(2)	SPIRE-1 and SPIRE-2	Those with background lipid-lowering treatment and have an LDL-C of >/ = 70 mg/dl (SPIRE-1) or LDL-C >/ = 100 mg/dl (SPIRE-2)	Bococizumab versus placebo	This study has been terminated. Completion date: Jan. 2017		Bococizumab being a humanized monoclonal antibody, a strong immune response was seen against it which mitigate the LDL-C lowering effect. Anti-drug Ab was seen in 48% patients and neutralizing Ab developed in 29% patients